Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

titration to comfort phase. Thereafter pain relief was provided using patient controlled analgesia (PCA) in a dose ratio of 2:1 (M6G:morphine). The secondary data announced today demonstrated again that in the initial phase after surgery the dose of M6G required to titrate patients to comfort was 3 times that required for morphine on a weight basis. However, during the prolonged PCA phase, the ratio was lower (0-24 hours 1.6:1; 24-48 hours 1.4:1). This shows that patients in the M6G group made less demands for pain relief after titration to comfort, as assessed by presses on the PCA button. These data support the hypothesis that M6G has a longer duration of analgesic action than morphine.

EMAIL ALERT: If you wish to unsubscribe please email cenes@cenes.com with your name and email address and we will arrange for your address to be removed or alternatively you can visit our website at http://www.cenes.com/contact/alert.htm and unsubscribe there.

Please arrange for the email address alert@cenes.com to pass though your spam filter.

- ------------------------------------------

IMPORTANT NOTICE.

Confidentiality: This e-mail and its attachments are intended for the above named only and may be confidential. If they have come to you in error you must take no action based on them, nor must you copy or show them to anyone; please reply to this e-mail and highlight the error.

Security Warning: Please note that this e-mail has been created in the knowledge that Internet e-mail is not a 100% secure communications medium. We advise that you understand and observe this lack of security when e-mailing us.

Viruses: Although we have taken steps to ensure that this e-mail and attachments are free from any virus, we advise that in keeping with good computing pra
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:11/24/2014)... Nov. 24, 2014  Marta Rendon, MD, founder of the ... Raton , FL and international key opinion leader in dermatology, ... the United States to attend the international ... Turkey . Here, at this gathering of over 600 ... renowned facial plastic surgery experts from Asia ...
(Date:11/24/2014)...  Surgical Theater, LLC, announced today that their technology ... opening of Europe,s first simulation ... The SuRgical Planner (SRP) and the Surgical Navigation Advanced ... their 3D navigation and augmented reality capabilities in the ... and Chair, Department of Neurosurgery at Mount Sinai Health ...
(Date:11/24/2014)... 24, 2014  Pifflers United Chronic and Invisible ... release of results of a study of ActiPatch®, ... self-management of fibromyalgia pain. The results demonstrated that ... very significant clinically meaningful pain reduction can be ... with fibromyalgia used ActiPatch® for 7 days and ...
Breaking Medicine Technology:Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 2Marta Rendon, MD Selected To Attend Prestigious, Global Aesthetic Experts Summit! 3Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... Tengion, Inc. (NASDAQ: TNGN ), a ... Vice President Finance and Chief Financial Officer of Tengion, ... Health Care Conference on Wednesday, November 30, 2011, at ... webcast of the presentation can be accessed at ...
... Nov. 21, 2011 /PRNewswire-Asia/ -- Sundia MediTech Company Inc., a ... the company was named one of the 50 best companies ... was announced at an October ceremony in Shanghai. This is ... after it was previously named in 2007 and 2008. ...
Cached Medicine Technology:Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:11/24/2014)... 2014 The Mesothelioma Applied Research ... International Symposium on Malignant Mesothelioma from March 2nd through ... sessions will take place on the campus of the ... a community dinner and an awards ceremony, will be ... cover a range of topics about pleural and peritoneal ...
(Date:11/24/2014)... 2014 A new sports massage ... pain-relief service and massage therapy provider, announced it ... This newest sports massage is a ... between traditional sports massage and ESM is that ... very own "reset button,” and ESM can increase ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 SWAccessControl.com ... locks. As a matter of fact, the company is a ... its brand new magnetic locks are available at discounted prices, ... our new range of magnetic locks. This time, all of ... are popular at home and abroad, so I have confidence ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/23/2014)... Dallas, TX (PRWEB) November 24, 2014 ... Trials Review, H2, 2014" provides data on the ... information and data relating to the clinical trials ... trial numbers and their recruitment status as per ... The databook offers a preliminary coverage of disease ...
Breaking Medicine News(10 mins):Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 2Health News:2015 International Symposium on Malignant Mesothelioma Will Take Place at the National Institutes of Health Campus 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4
... put the outbreak in doubt. The mystery began Sept. ... cough, typically heralded by a runny// nose, sneezing, slight fever, ... ,Then in last September through early November, about three ... other symptoms suggesting that they, too, were stricken with the ...
... groups, with relatively little genetic differentiation among the people from ... study. ,Although the study used participants that may ... suggest that the frequencies of many genetic variants are distinctive ... Indian American scientist who led the study said. ...
... that neural stem cells will eventually be useful for ... and multiple sclerosis. But there may also be another ... cells. ,A Perspective article in PLoS Medic ine, ... discusses a new study in mice, published in the ...
... Drug Administration (FDA) will release its approval for consumption of ... ,Two federal scientists, Larisa Rudenko and John C. Matheson. ... milk of cloned animals and their offspring. “On no basis ... from normal animals,” they say. ,A formal recommendation ...
... was 14 months old that left her gasping for breath.// ... to trigger an allergic reaction in people allergic to it. ... a landmark experiment that set to discover-'Could eating tiny amounts ... bodies to overcome severe food allergies?' ,Preliminary results ...
... children may have a shorter life span than those with few ... new study.// ,Researchers led by Dustin Penn and Ken Smith ... living in Utah between 1860 and 1985, who bore a total ... an average of eight children each, but family size ranged from ...
Cached Medicine News:Health News:Indians Make One Major Human Race: US Study 2Health News:Is Your Child Allergic To Peanuts? 2
... that need an advanced ... Vision,Premier Holter System provides ... Vision Premier system,adds expanded ... comprehensive list of diagnostic,codes ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... three contrast levels (high, 9.5 % and 6%) ... test is designed to detect very subtle changes ... evaluation or due to refractive surgery. The upper ... contrast and acuity levels as the lower two ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: